Document text
Principal Investigator: Michael R. Farzan
Organization: SCRIPPS FLORIDA
Fiscal Year: 2020
Award: $343,458
Funding agency: National Institute of Allergy and Infectious Diseases
SARS-CoV-2 (2019-nCoV) is a human pathogenic coronavirus that is very similar to the SARS coronavirus
(SARS-CoV or SARS-CoV-1). As of this writing, more than 40,000 people are reported to be infected with this
virus, causing more than 1,000 deaths. It is hoped that the number of new cases will decline precipitously in
the coming weeks and months, and that newly available therapies can prevent more deaths. However, it is
already clear that SARS-CoV-2 will remain a concern, real or potential, over the several next years.
The team assembled here has extensive experience the study of SARS-CoV. We identified its receptor – also
the receptor for SARS-CoV-2 – as ACE2 (Li et al., Nature 2003), delineated the receptor-binding domain
(RBD) on the SARS-CoV spike (S) protein (Wong et al., J Biol Chem 2004), created the first efficient retroviral
pseudotype system to study SARS-CoV S protein-mediated entry (Moore et al., J Virol 2004), identified and
characterized a broad neutralizing antibody recognizing the RBD in collaboration with Wayne Marasco (Sui
et al, PNAS, 2004), described the structure of the RBD bound to ACE2 with Stephen Harrison (Li et al.,
Science, 2005), described critical S-protein determinants of zoonosis and disease severity (Li et al., EMBO
J, 2005), showed in separate collaborations with David Ho and Shibo Jiang that the S protein or the RBD
alone can raise potent neutralizing antisera (Chen et al., J Virol 2005; He et al., J Immunol, 2006), and
observed that cathepsin L was necessary for S protein-mediated infection (Huang et al., J Biol Chem, 2006).
The current proposal seeks to apply this experience and the tools and approaches we developed for SARS-CoV to: (1) develop, characterize, and optimize protein inhibitors of SARS-CoV-2 entry including
immunoadhesin forms of ACE2, the SARS-CoV-2 RBD region, anti-ACE2 antibodies, and anti-S protein
antibodies, (2) determine whether S-protein-trimers or the RBD, or a combination thereof, most efficiently
raise SARS-CoV-2 neutralizing antibodies.
Terms: <2019 novel coronavirus><2019-nCoV><Administrative Supplement><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Angiotensin Receptor><Antibodies><Antigens><Antisera><Binding><Binding Proteins><Bioavailability><Biologic Availability><Biological Availability><CATL><CD143 Antigens><CTSL Protein><Carboxycathepsin><Case Fatality Rates><Cathepsin L><Cell Body><Cells><Cessation of life><China><Clinical Trials><CoV S protein><CoV emergence><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><Collaborations><Common Rat Strains><Coronaviridae><Coronavirus><Coronavirus glycoprotein S><Coronavirus spike protein><Death><Development><Dipeptidyl Peptidase A><Domestic Rabbit><Emergencies><Emergency Situation><Epidemic><Exposure to><Glycoproteins><HIV-1><HIV-I><HIV1><Half-Life><Healthcare><Human><Human Immunodeficiency Virus Type 1><Human immunodeficiency virus 1><Immune Sera><In Vitro><Infection><Infection prevention><Kininase A><Kininase II><Ligand Binding Protein><Ligand Binding Protein Gene><Mainland China><Major Excreted Protein><Mediating><Mice><Mice Mammals><Modern Man><Molecular Interaction><Murine><Mus><NIH><National Institutes of Health><Nature><Oryctolagus cuniculus><Pathogenicity><Peptidyl-Dipeptidase A><Phage Display><Physiologic Availability><Prevent infection><Primates><Primates Mammals><Protein Binding><Proteins><Rabbits><Rabbits Mammals><Rat><Rats Mammals><Rattus><Receptor Protein><Reporting><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Science><Series><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe acute respiratory syndrome coronavirus 2><Severity of illness><Structure><System><Technology><Testing><Uncertainty><United States National Institutes of Health><Vaccines><Variant><Variation><Viral><Virus><Work><Writing><Wuhan coronavirus><base><bound protein><corona virus><coronavirus S protein><coronavirus emergence><coronavirus spike glycoprotein><develop therapy><developmental><disease severity><doubt><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><experience><health care><immune serum><immunogen><improved><in vivo><inhibitor><inhibitor/antagonist><insight><intervention development><nCoV><neutralizing antibody><new CoV><new coronavirus><novel CoV><novel coronavirus><pathogenic virus><prevent><preventing><prophylactic><receptor><receptor binding><receptor bound><research facility><severe acute respiratory syndrome-CoV><therapy development><tool><treatment development><viral pathogen>